| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/24/2013 | US20130023564 Piperidinyl derivative as a modulator of chemokine receptor activity |
| 01/24/2013 | US20130023556 Autotaxin inhibitors |
| 01/24/2013 | US20130023555 Kinase inhibitor with improved solubility profile |
| 01/24/2013 | US20130023554 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof |
| 01/24/2013 | US20130023549 Pharmaceutical Compositions Comprising Nilotinib or Its Salt |
| 01/24/2013 | US20130023548 Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 01/24/2013 | US20130023533 New 5-alkynyl-pyridines |
| 01/24/2013 | US20130023531 Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors |
| 01/24/2013 | US20130023530 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| 01/24/2013 | US20130023526 Isoxazolines as Therapeutic Agents |
| 01/24/2013 | US20130023523 Pyridazino[4,5-d]pyrimidin-5(6h)-one inhibitors of kinases |
| 01/24/2013 | US20130023521 Novel selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
| 01/24/2013 | US20130023520 Anaesthetic eye solution and method of use |
| 01/24/2013 | US20130023519 5-alkynyl-pyridines |
| 01/24/2013 | US20130023518 Novel 3,3-dimethyl tetrahydroquinoline derivatives |
| 01/24/2013 | US20130023514 Substituted pyrrolotriazines as protein kinase inhibitors |
| 01/24/2013 | US20130023511 Organometallic complexes as therapeutic agents |
| 01/24/2013 | US20130023506 Method for treating uterine fibroids |
| 01/24/2013 | US20130023504 Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways |
| 01/24/2013 | US20130023500 Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof |
| 01/24/2013 | US20130023499 Certain substituted amides, method of making, and method of use thereof |
| 01/24/2013 | US20130023498 MicroRNA Modulators and Method for Identifying and Using the Same |
| 01/24/2013 | US20130023497 Triazine Derivatives and their Therapeutical Applications |
| 01/24/2013 | US20130023483 Template-fixed peptidomimetics with cxcr7 modulating activity |
| 01/24/2013 | US20130023481 Adenovirus E1A Fragments for Use in Anti-Cancer Therapies |
| 01/24/2013 | US20130023480 Purified Bowman-Birk Protease Inhibitor Proteins Isolated from a Soy Processing Sttream |
| 01/24/2013 | US20130023479 Use of nucleolin as a biomarker for lymphangiogenesis in cancer prognosis and therapy |
| 01/24/2013 | US20130023461 Oligopeptide compounds and uses thereof |
| 01/24/2013 | US20130022689 Use of Amisulpride as an Anti-Emetic |
| 01/24/2013 | US20130022688 Use of Amisulpride as an Anti-Emetic |
| 01/24/2013 | US20130022672 Stabilized Amorphous Forms of Imatinib Mesylate |
| 01/24/2013 | US20130022663 Method of making and using a topical medicated formula and delivery system to use to prevent and treat breast diseases and breast cancer as well as use as skin wellness and anti-wrinkle formula |
| 01/24/2013 | US20130022641 Anti-Tumor Agent and Immunostimulating Agent |
| 01/24/2013 | US20130022640 Immune modulators relating to foxo3a |
| 01/24/2013 | US20130022638 Tuberculosis Vaccine |
| 01/24/2013 | US20130022629 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| 01/24/2013 | US20130022627 Combination Therapy With Antibody-Drug Conjugates |
| 01/24/2013 | US20130022624 Anti-epidermal growth factor receptor antibodies and uses thereof |
| 01/24/2013 | US20130022623 Antibodies that specifically bind to tim3 |
| 01/24/2013 | US20130022617 Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis |
| 01/24/2013 | US20130022611 Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator |
| 01/24/2013 | US20130022609 Method of treating androgen independent prostate cancer |
| 01/24/2013 | US20130022601 Trivalent, bispecific antibodies |
| 01/24/2013 | US20130022600 Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| 01/24/2013 | US20130022598 Dual Specific Immunotoxin for Brain Tumor Therapy |
| 01/24/2013 | US20130022597 Antibodies Directed To GPNMB And Uses Thereof |
| 01/24/2013 | US20130022596 Methods and compositions for diagnostic use in cancer patients |
| 01/24/2013 | US20130022595 Variants of humanized immunomodulatory monoclonal antibodies |
| 01/24/2013 | US20130022594 Selective fak inhibitors |
| 01/24/2013 | US20130022587 Cycloalkyl-Substituted Imidazole Derivative |
| 01/24/2013 | US20130022585 Regeneration and repair of neural tissue using postpartum-derived cells |
| 01/24/2013 | US20130022582 Multipotent nestin-positive cells |
| 01/24/2013 | US20130022551 DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
| 01/24/2013 | US20130022545 DRUG DELIVERY SYSTEM FOR TREATMENT OF LIVER CANCER BASED ON INTERVENTIONAL INJECTION OF TEMPERATURE AND pH-SENSITIVE HYDROGEL |
| 01/24/2013 | US20130022544 Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| 01/24/2013 | US20130022541 FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death |
| 01/24/2013 | US20130022539 Ovr115 antibody compositions and methods of use |
| 01/24/2013 | US20130022538 Aptamer-mrna conjugates for targeted protein or peptide expression and methods for their use |
| 01/24/2013 | CA2842352A1 3-(fluorvinyl)pyrazoles and the use thereof |
| 01/24/2013 | CA2842345A1 Peptides shared among lethal cancers and therapeutic compositions comprising said peptides |
| 01/24/2013 | CA2842306A1 Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
| 01/24/2013 | CA2842228A1 Combination treatment for cancer |
| 01/24/2013 | CA2842195A1 Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death |
| 01/24/2013 | CA2842190A1 Heterocyclic compounds and uses thereof |
| 01/24/2013 | CA2842169A1 Anti-cxcr4 antibodies and methods of use |
| 01/24/2013 | CA2841960A1 Novel compositions and methods for treating prostate cancer |
| 01/24/2013 | CA2841887A1 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors |
| 01/24/2013 | CA2841886A1 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| 01/24/2013 | CA2841745A1 Rspo binding agents and uses thereof |
| 01/24/2013 | CA2841629A1 Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| 01/24/2013 | CA2841449A1 Platinum(iv) complexes and pharmaceutical composition containing the same |
| 01/23/2013 | EP2548890A1 Anti MIF antibodies |
| 01/23/2013 | EP2548877A1 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| 01/23/2013 | EP2548868A1 Method and process for preparation and production of deuterated -diphenylurea |
| 01/23/2013 | EP2548867A1 Method for preparing deuterated diphenylurea |
| 01/23/2013 | EP2548582A1 Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation |
| 01/23/2013 | EP2548576A1 Diagnosis of cancer using anti-desmoglein-3 antibodies |
| 01/23/2013 | EP2548574A1 New humanized anti-cd20 monoclonal antibody |
| 01/23/2013 | EP2548561A1 Semuloparin for improving the survival of patients with locally advanced cancer |
| 01/23/2013 | EP2548558A1 Nitrogen-containing condensed heterocyclic as inhibitors of bruton's tyrosine kinase |
| 01/23/2013 | EP2548455A1 Equol-producing lactic acid bacteria-containing composition |
| 01/23/2013 | EP2547700A1 Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein |
| 01/23/2013 | EP2547691A1 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers |
| 01/23/2013 | EP2547684A1 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| 01/23/2013 | EP2547680A1 Imidazopyrazines |
| 01/23/2013 | EP2547676A2 Modulators of hec1 activity and methods therefor |
| 01/23/2013 | EP2547674A1 Process for the preparation of malic acid salt of sunitinib |
| 01/23/2013 | EP2547668A1 Toluidine blue derivatives as photosensitising compounds |
| 01/23/2013 | EP2547664A1 Morpholinylquinazolines |
| 01/23/2013 | EP2547661A2 Indazole compounds and their uses |
| 01/23/2013 | EP2547660A1 Nitroxyl (hno) releasing compounds and uses thereof in treating diseases |
| 01/23/2013 | EP2547369A1 A nanoparticle comprising a micelle formed by an amphiphilic block- copolymer and encapsulating a gadolinium complex |
| 01/23/2013 | EP2547353A2 Cancer treatment with recombinant vector |
| 01/23/2013 | EP2547349A1 Cancer therapy with a parvovirus combined with an hdac inhibitor |
| 01/23/2013 | EP2547342A2 Combined use of phospholipid and sulfate groups-carrying polysaccharides for inhibiting metastatic spread |
| 01/23/2013 | EP2547334A1 Novel compounds and compositions for targeting cancer stem cells |
| 01/23/2013 | EP2547328A2 Ccr7 ligand delivery and co-delivery in immunotherapy |
| 01/23/2013 | EP2158900B1 Polymeric delivery formulations of leuprolide with improved efficacy |
| 01/23/2013 | CN1919339B Cucurbitacin nano preparation comprising protein, preparation method and use thereof |
| 01/23/2013 | CN102892898A Diagnostic kit including micro-rna biomarkers and used for diagnosis of hepatocellular carcinoma, and method |